SCHEMBL3029355

SCHEMBL3029355

Nc1cc(F)c(N2CCS(=O)(=O)CC2)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
KDM4E B2RXH2 1/20 0.35
ATR Q13535 1/20 0.34
ALDH1A1 P00352 3/20 0.33
MAOA P21397 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CDK1 P06493 1/20 0.33
CDK2 P24941 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
GFER P55789 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
FAAH O00519 1/20 0.32
ALOX5AP P20292 3/20 0.31
FEN1 P39748 3/20 0.31
LRRK2 Q5S007 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL6653299 0.89 MAOA (0.39) MAPTKDM4EATRALDH1A1MAOA
SCHEMBL13515431 0.81 MEN1 (0.39) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL21662565 0.80 MAPT (0.33) MAPTALDH1A1MAOASMN1; SMN2LMNA
SCHEMBL28980419 0.79 MAPT (0.35) MAPTALDH1A1MAOASMN1; SMN2LMNA
SCHEMBL21634758 0.78 LRRK2 (0.35) MAPTALDH1A1MAOASMN1; SMN2LRRK2
SCHEMBL22689408 0.78 SLC6A9 (0.32) MAOAALOX5AP
SCHEMBL30199085 0.77 ALDH1A1 (0.58) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL2255157 0.77 ALDH1A1 (0.58) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL21634788 0.77 MAOA (0.32) MAPTMAOA
SCHEMBL3038716 0.77 KDM4E (0.41) KDM4EALDH1A1LMNAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6774231-B2 BACTERICIDES PHARMACIA & UPJOHN COMPANY 2004-08-10 US claimed
EP-4568961-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS Merck Sharp & Dohme LLC (US) 2025-06-18 EP disclosed
WO-2024035618-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-02-15 WO disclosed
WO-2024035618-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-02-15 WO disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound PHARMACIA & UPJOHN COMPANY 2004-01-22 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed
US-6605609-B2 N-(((5S)-3-(4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophen yl) -2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide antimicrobial used in combination therapy PHARMACIA & UPJOHN COMPANY 2003-08-12 US disclosed
EP-1294717-A2 A THIAZINE OXAZOLIDINONE PHARMACIA & UPJOHN COMPANY (US) 2003-03-26 EP disclosed
WO-2003006440-A2 AMIDE-CONTAINING COMPOUND HAVING IMPROVED SOLUBILITY AND METHOD OF IMPROVING THE SOLUBILITY OF AN AMIDE-CONTAINING COMPOUND PHARMACIA & UPJOHN COMPANY (US) 2003-01-23 WO disclosed
US-20030004160-A1 Method for the preparation of oxazolidinones PHARMACIA & UPJOHN COMPANY 2003-01-02 US disclosed
US-20020156072-A1 Thiazine oxazolidinone PHARMACIA & UPJOHN COMPANY 2002-10-24 US disclosed
WO-2001098297-A2 A THIAZINE OXAZOLIDINONE PHARMACIA & UP JOHN COMPANY (US) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156072-A1 Thiazine oxazolidinone OXA1L, TLR5, TALDO1 MAPT 4319/4885KDM4E 4350/4885ATR 2595/4885
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ATR 3427/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ATR 3427/4885
US-20030004160-A1 Method for the preparation of oxazolidinones CYP3A5, OXA1L, OGFOD1 MAPT 3208/4885KDM4E 2833/4885ATR 4244/4885
US-20040014967-A1 Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound AADAC, AAAS, SLC7A1 MAPT 1484/4885KDM4E 971/4885ATR 1251/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAPT 4491/4885KDM4E 905/4885ATR 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.